A Fundamental Economic Challenge
Developing medications for rare diseases faces a fundamental economic challenge that does not affect drugs for common conditions: the enormous cost of drug development, often exceeding a billion dollars per approved medication, must be recouped from a very small patient population, creating a difficult calculus for pharmaceutical companies deciding where to invest limited research resources without specific incentives designed to address rare disease treatment gaps.
Policy Responses to the Market Failure
Recognizing this market failure, many countries have implemented orphan drug policies offering incentives including extended market exclusivity, tax credits for development costs, and expedited regulatory review specifically for treatments targeting rare conditions. These policies have meaningfully increased the number of rare disease treatments developed and approved compared to the era before such incentives existed, demonstrating that thoughtful policy can address gaps that market forces alone would not fill.
The Access and Cost Tension
Even with successful development, orphan drugs are frequently priced very high given the need to recoup development costs across few patients, creating genuine tension between incentivizing needed innovation and ensuring the resulting treatments remain accessible to the patients who need them. Navigating this tension between innovation incentives and affordable access remains an ongoing policy challenge as more rare disease treatments reach the market. Facilities can source lab supplies and pharmacy supplies from our catalog.
